Erythropoietin-induced hypertensive urgency in a patient with chronic renal insufficiency: Case report and review of the literature

Pharmacotherapy

Volumn 23, Issue 2, 2003, Pages 265-269

  Novak, Barbara L ^a   Force, Rex W ^a   Mumford, Brett T ^a   Solbrig, Ronald M ^a  

^a IDAHO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; ERYTHROPOIETIN; FERROUS SULFATE; FUROSEMIDE; GLYCERYL TRINITRATE; HUMAN INSULIN; LEVOTHYROXINE SODIUM; LORATADINE; NIFEDIPINE; NITROPRUSSIDE SODIUM; SPIRONOLACTONE;

AGED; ANEMIA; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CASE REPORT; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG INFUSION; FEMALE; HEART FAILURE; HEMATOCRIT; HOSPITALIZATION; HUMAN; HYPERTENSION; HYPOTHYROIDISM; KIDNEY FUNCTION; SUSTAINED DRUG RELEASE; TITRIMETRY; UREA NITROGEN BLOOD LEVEL;

AGED; EMERGENCY TREATMENT; ERYTHROPOIETIN; FEMALE; HOSPITALIZATION; HUMANS; HYPERTENSION; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC;

EID: 0037322006     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.2.265.32077     Document Type: Article

References (16)

1. Kleinman KS, Schweitzer SU, Perdue ST, Bleifer KH, Abels RI. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind, placebo-controlled trial. Am J Kidney Dis 1989:14(6):486-95.
2. Winearls CG, Oliver DO, Pippard MJ, Reid D, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986;2:1175-8.
3. Cody J, Daly C, Campbell M, et al. Recombinant human erythropoietin for chronic renal failure anaemia in predialysis patients. In: The Cochrane Library, 2, 2002. Oxford, UK: Update Software. Available from www.cochrane.org. Accessed November 2001.
4. Raine AE, Roger SD. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991;18(suppl 1):76-83.
5. National Kidney Foundation. Dialysis outcomes quality initiative. New York: National Kidney Foundation, 1997.
6. Markham A, Bryson HM. Epoetin alpha: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 1995; 49(2):232-53.
7. Schwartz AB, Prior J, Terzian L, Kahn B. Erythropoietin for the anemia of chronic renal failure. Am Fam Physician 1998;37(6):211-15.
8. Watson AJ. Adverse effects of therapy for the correction of anemia in hemodialysis patients. Semin Nephrol 1989;9(1 suppl 1):30-4.
9. Raine AE. Hypertension, blood viscosity, and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet 1988;1:97-100.
10. Lim VS, Kirchner PT, Fangman J, Richmond J, DeGowin RL. The safety and the efficacy of maintenance therapy of recombinant human erythropoietin in patients with renal insufficiency. Am J Kidney Dis 1998;14(6):496-506.
11. Conlon P, Kovalik E, Schumm D, Minda S, Schwab S. Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure. Ren Fail 2000;22(4):435-44.
12. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239-45.
13. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989;321(3):158-63.
14. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316(2):73-8.
15. Ksiazek A, Zaluska W, Ksiazek P. Effect of recombinant human erythropoietin on adrenergic activity in normotensive hemodialysis patients. Clin Nephrol 2001;56(2):104-10.
16. Zachee P. Controversies in selection of epoetin dosages: issues and answers. Drugs 1995;49(4):536-47.